Multinational randomized trial of cytoreductive surgery for relapsed ovarian cancer

Treatment for patients with recurrent ovarian cancer has been mainly based on systemic therapy. The multinational DESKTOP III trial randomized patients with recurrent ovarian cancer who had a first relapse after a platinum-free interval of at least 6 months to secondary cytoreductive surgery followed by platinum-based surgery or to platinum-based surgery alone. The median overall survival was 53.7 months in the surgery group and 46.0 months in the no-surgery group (HR 0.75; p=0.02). Patients with a complete resection (75.5% of the patients in the surgery group) had the most favorable outcome, with a median OS of 61.9 months. Quality of life trhough 1 year of follow-up did not differ between the two groups, and there was no mortality within 30 days of surgery (Quick take video summary).